Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...

Broadway's brightest voices are taking the stage in support of those living with pulmonary fibrosis (PF), a life-threatening ...

In an interview with Targeted Oncology, Sarbajit Mukherjee, MD, GI medical oncologist at Baptist Health Miami Cancer ...

Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary ...

A recent study published in The Lancet Respiratory Medicine has suggested that short telomere length may increase the risk of idiopathic pulmonary fibrosis (IPF) even in patients who do not carry rare ...

Discover how a surgical team engineered an improvised artificial lung system that kept a man alive for 48 hours without lungs ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common ...

The Casppian study design included periodic evaluations and long-term safety monitoring for up to a total of 12 months following the first injection. -- There has been no safety concern with the use ...

Zinzino group revenue increased with a total of 20 %, compared with the previous year. The revenue in January for Zinzino's sales markets increased by 20% and amounted to SEK 274.1 (229.2) million.

An increase in NLR values may be indicative of disease onset among patients with SSc and may help identify those at risk for poor outcomes.

Organon has launched the third edition of its Women's Health Accelerator Program, expanding it to include the Middle East, Turkey and Africa (META). With support from Flat6Labs, the 2026 program will ...